BCYC
Price
$7.62
Change
-$0.46 (-5.69%)
Updated
Jul 15, 01:59 PM (EDT)
Capitalization
559.57M
16 days until earnings call
PHIO
Price
$2.36
Change
-$0.05 (-2.07%)
Updated
Jul 15, 12:46 PM (EDT)
Capitalization
11.56M
Interact to see
Advertisement

BCYC vs PHIO

Header iconBCYC vs PHIO Comparison
Open Charts BCYC vs PHIOBanner chart's image
Bicycle Therapeutics
Price$7.62
Change-$0.46 (-5.69%)
Volume$100
Capitalization559.57M
Phio Pharmaceuticals
Price$2.36
Change-$0.05 (-2.07%)
Volume$100
Capitalization11.56M
BCYC vs PHIO Comparison Chart in %
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. PHIO commentary
Jul 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Buy and PHIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 15, 2025
Stock price -- (BCYC: $8.08 vs. PHIO: $2.41)
Brand notoriety: BCYC and PHIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 70% vs. PHIO: 14%
Market capitalization -- BCYC: $559.57M vs. PHIO: $11.56M
BCYC [@Biotechnology] is valued at $559.57M. PHIO’s [@Biotechnology] market capitalization is $11.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.86B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whilePHIO’s FA Score has 0 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • PHIO’s FA Score: 0 green, 5 red.
According to our system of comparison, BCYC is a better buy in the long-term than PHIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 5 TA indicator(s) are bullish while PHIO’s TA Score has 3 bullish TA indicator(s).

  • BCYC’s TA Score: 5 bullish, 5 bearish.
  • PHIO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, BCYC is a better buy in the short-term than PHIO.

Price Growth

BCYC (@Biotechnology) experienced а +12.69% price change this week, while PHIO (@Biotechnology) price change was -5.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.91%. For the same industry, the average monthly price growth was +18.97%, and the average quarterly price growth was +31.99%.

Reported Earning Dates

BCYC is expected to report earnings on Oct 30, 2025.

PHIO is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+2.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCYC($560M) has a higher market cap than PHIO($11.6M). PHIO YTD gains are higher at: 33.889 vs. BCYC (-42.286). PHIO has higher annual earnings (EBITDA): -7.05M vs. BCYC (-200.61M). BCYC has more cash in the bank: 793M vs. PHIO (13.3M). PHIO has less debt than BCYC: PHIO (0) vs BCYC (8.33M). BCYC has higher revenues than PHIO: BCYC (25.7M) vs PHIO (0).
BCYCPHIOBCYC / PHIO
Capitalization560M11.6M4,828%
EBITDA-200.61M-7.05M2,846%
Gain YTD-42.28633.889-125%
P/E RatioN/A0.01-
Revenue25.7M0-
Total Cash793M13.3M5,962%
Total Debt8.33M0-
FUNDAMENTALS RATINGS
BCYC vs PHIO: Fundamental Ratings
BCYC
PHIO
OUTLOOK RATING
1..100
1855
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
6455
P/E GROWTH RATING
1..100
10066
SEASONALITY SCORE
1..100
31n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (21) in the null industry is somewhat better than the same rating for PHIO (57) in the Biotechnology industry. This means that BCYC’s stock grew somewhat faster than PHIO’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as PHIO (100) in the Biotechnology industry. This means that BCYC’s stock grew similarly to PHIO’s over the last 12 months.

BCYC's SMR Rating (96) in the null industry is in the same range as PHIO (98) in the Biotechnology industry. This means that BCYC’s stock grew similarly to PHIO’s over the last 12 months.

PHIO's Price Growth Rating (55) in the Biotechnology industry is in the same range as BCYC (64) in the null industry. This means that PHIO’s stock grew similarly to BCYC’s over the last 12 months.

PHIO's P/E Growth Rating (66) in the Biotechnology industry is somewhat better than the same rating for BCYC (100) in the null industry. This means that PHIO’s stock grew somewhat faster than BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCPHIO
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 15 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
87%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 7 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SRORX13.290.02
+0.15%
Calamos Antetokounmpo Sustainable Eqs R6
ODINX83.20N/A
N/A
Invesco Discovery R
CFIPX26.75N/A
N/A
Franklin Global Equity A
PJEQX15.46N/A
N/A
PGIM US Real Estate R6
OAZEX23.00-0.12
-0.52%
Oakmark International Small Cap R6